Anti-miR-21-induced reduction in tumor growth, interestingly, was also shown by Si et al. to be potentiated by the addition of the chemotherapeutic agent topotecan, an inhibitor of DNA topoisomerase I. This suggests that suppression of the oncogenic miR-21 could sensitize tumor cells to anticancer therapy, which is an exciting prospect for patients exhibiting a poor response to primary chemotherapy. Here, TOP1 is linked to neoplasm.